Pulse Biosciences

US · PLSE #2388 by market cap Listed 2016

49.09 -0.66 -1.33%

Live - 5344 symbols - heartbeat 246s ago · 2026-10-08 07:00

Pre-market 49.00 -0.18%

After-hours 49.09 0.00%

Market cap: 3.50B
P/E (TTM): -41.96
P/B: 35.19
EPS: -1.08
Div yield: 0.00%
52W pos: 79%

Reader sentiment Are you bullish or bearish on PLSE?

Anonymous reader poll. Unscientific, not investment advice.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Founded: 2014
CEO: Mr. Paul A. Laviolette
Employees: 116
Headquarters: Miami, Florida, United States of America
Fiscal year end: 12-31
Website: pulsebiosciences.com

Company profile

Exchange: US
Symbol: PLSE
Market-cap rank: #2388
Listing date: 2016-05-18
Market cap: 3.50B
Float cap: 1.01B
Shares out: 71.32M
Float shares: 20.65M

Sectors & themes

Medical Instruments & Supplies Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.